We performed CMap analysis to validate the drugs predicted by molecular docking, which indicated that eltrombopag might serve as a potential therapeutic drug in SKCM patients with highly expressed CLSPN, and darifenacin might act as potential therapeutic drug in PRAD, CESC, BRCA, COAD, LUAD, PAAD patients with CLSPN high expression (Fig. 11F). The gene discussed is CLSPN; the disease is colon adenocarcinoma.